한글목차

세계의 DNA 시퀀싱 시장은 2024년에 237억 2,800만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 16.4%로 성장하여 2031년까지 698억 6,300만 달러로 확대될 것으로 예측됩니다.

DNA 시퀀싱은 DNA 분자 내 뉴클레오티드(A, T, C, G)의 염기서열을 결정하기 위해 사용되는 핵심 기술입니다. 유전체을 종합적으로 분석하여 개인의 유전적 변이 및 질병 관련 변이를 밝혀내는 기술입니다. 주요 플랫폼에는 차세대 시퀀싱(NGS)과 3세대 시퀀싱(TGS)이 포함되며, 높은 처리량, 정확도, 확장성을 제공합니다. DNA 시퀀싱은 질병 진단, 암 정밀의료, 생식의학, 미생물학, 농업 육종, 법의학 등 다양한 분야에 적용되고 있습니다. 정밀의료, 바이오의약품 연구개발, 바이오인포매틱스 산업의 발전을 뒷받침하는 기반기술로서 생명과학 연구의 패러다임을 크게 변화시키고 있습니다.

정밀의료, 생물다양성 연구, 개인 맞춤형 의료에 대한 전 세계적인 수요 증가, 공중보건 및 질병 예방 분야의 정부 자금 증가, 시퀀싱 비용의 급격한 감소, AI 및 클라우드 컴퓨팅을 통한 분석 효율성 향상, 액체 생검 및 비침습적 산전검사(NIPT)와 같은 고성장 용도의 급속한 보급 등을 주요 촉진요인으로 꼽을 수 있습니다. NIPT)와 같은 고성장 용도의 급속한 보급을 들 수 있습니다. 규제 환경도 성숙해지면서 상용화가 가속화되고 있습니다.

기술 혁신이 계속되는 가운데, DNA 시퀀싱 산업은 원자재 가격 변동, 데이터 보안 컴플라이언스, 지적재산권 장벽, 임상적 해석의 불일치 등의 현저한 문제에 직면해 있습니다. 하이엔드 시퀀싱 플랫폼은 안정적인 공급망에 크게 의존하고 있으며, 칩, 효소 등 핵심 부품은 소수공급업체가 독점하고 있기 때문에 지정학적 혼란에 영향을 받기 쉽습니다. 선진국에서는 유전자 프라이버시 관련 엄격한 법규가 도입되어 세계 서비스 제공업체에게 컴플라이언스 부담이 발생하고 있습니다. 중국 등 신흥 시장에서도 고급 검사 서비스에 대한 급여 제도와 임상 도입 경로 측면에서 제약에 직면해 있습니다.

암 검진, 희귀질환 진단, 선천성 기형 예방, 생식의학 등 고부가가치 분야에서는 특정 질환에 특화된 맞춤형 솔루션에 대한 수요가 확대되고 있습니다. 제약사 및 CRO(의약품 개발 수탁기관)의 전장유전체 시퀀싱 및 단일세포 시퀀싱에 대한 수요도 빠르게 증가하고 있으며, AI를 활용한 진단 기술 및 CDx(동반진단) 플랫폼과의 융합을 촉진하고 있습니다. 각국의 인체유전자원 관리 관련 규제는 지역 데이터베이스 구축 및 생태계 강화를 추진하고 있습니다. 가까운 미래에 시퀀싱 데이터는 의료적 판단과 신약개발의 기반이 될 것이며, 서비스형 데이터(Data-as-a-Service, DaaS)와 유전체 클라우드 플랫폼과 같은 새로운 비즈니스 모델을 주도할 것입니다.

이 보고서는 DNA 시퀀싱 세계 시장에 대한 종합적인 분석을 제공하는 것을 목표로 합니다. 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추어 지역별, 국가별, 유형별, 용도별 DNA 염기서열 분석에 초점을 맞추었습니다.

DNA 시퀀싱 시장 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하는 매출 수익으로 제시되었습니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략을 수립하고, 시장 경쟁 구도를 평가하고, 현재 시장에서의 위치를 분석하고, DNA 시퀀싱과 관련된 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕고 있습니다.

시장 세분화

기업별

• Illumina
• Thermo Fisher Scientific
• Eurofins Scientific
• BGI
• Natera
• Berry Genomics
• Roche
• Novo Gene
• MGI-Tech
• LabCorp
• Pacific Biosciences
• Azenta Life Sciences
• Oxford Nanopore
• Macrogen

유형별 부문

• 제1세대 DNA 시퀀싱
• 제2세대 DNA 시퀀싱
• 제3세대 DNA 시퀀싱

용도별 부문

• 학술연구
• 임상연구
• 병원 및 진료소
• 제약 및 바이오테크놀러지
• 기타

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 네덜란드
  • 북유럽 국가
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 튀르키예
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동 및 아프리카

영문목차

The global market for DNA Sequencing was estimated to be worth US$ 23728 million in 2024 and is forecast to a readjusted size of US$ 69863 million by 2031 with a CAGR of 16.4% during the forecast period 2025-2031.

DNA Sequencing is a core technology used to determine the order of nucleotides (A, T, C, G) in a DNA molecule. By comprehensively analyzing genomes, this technology reveals individual genetic variations and disease-related mutations. The dominant platforms include Next-Generation Sequencing (NGS) and Third-Generation Sequencing (TGS), which offer high throughput, precision, and scalability. DNA sequencing is widely applied in disease diagnosis, cancer precision medicine, reproductive health, microbiology, agricultural breeding, and forensic science. It has become a foundational driver for the advancement of precision medicine, biopharmaceutical R&D, and the bioinformatics industry, profoundly transforming the research paradigm in life sciences.

With growing global demand for precision medicine, biodiversity research, and personalized healthcare. Key drivers include increased government funding in public health and disease prevention, dramatic reductions in sequencing costs, enhanced interpretation efficiency enabled by AI and cloud computing, and the rapid adoption of high-growth applications such as liquid biopsy and non-invasive prenatal testing (NIPT). Regulatory environments are also maturing, facilitating faster commercialization.

Despite continuous technological advancements, the DNA sequencing industry faces notable challenges, including raw material price volatility, data security compliance, IP barriers, and inconsistencies in clinical interpretation. High-end sequencing platforms heavily depend on stable supply chains, with critical components such as chips and enzymes monopolized by a few suppliers, making them vulnerable to geopolitical disruptions. In developed regions, stricter legislation on genetic privacy introduces compliance burdens for global service providers. Emerging markets like China also face constraints in terms of reimbursement systems and clinical adoption pathways for advanced testing services.

In high-value application areas like cancer screening, rare disease diagnostics, birth defect prevention, and reproductive health, downstream demand is shifting toward customized solutions tailored to specific diseases. Demand for whole-genome and single-cell sequencing is also rising rapidly among pharmaceutical companies and CROs, driving convergence with AI-enabled diagnostics and CDx platforms. National regulations on human genetic resource management are propelling local database initiatives and ecosystem upgrades. In the foreseeable future, sequencing data will become the foundation of medical decision-making and drug discovery, fueling new business models such as Data-as-a-Service (DaaS) and genomic cloud platforms.

This report aims to provide a comprehensive presentation of the global market for DNA Sequencing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of DNA Sequencing by region & country, by Type, and by Application.

The DNA Sequencing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DNA Sequencing.

Market Segmentation

By Company

• Illumina
• Thermo Fisher Scientific
• Eurofins Scientific
• BGI
• Natera
• Berry Genomics
• Roche
• Novo Gene
• MGI-Tech
• LabCorp
• Pacific Biosciences
• Azenta Life Sciences
• Oxford Nanopore
• Macrogen

Segment by Type

• First Generation DNA Sequencing
• Second Generation DNA Sequencing
• Third Generation DNA Sequencing

Segment by Application

• Academic Research
• Clinical Research
• Hospitals and Clinics
• Pharmaceuticals and Biotechnology
• Other

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of DNA Sequencing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of DNA Sequencing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of DNA Sequencing in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 DNA Sequencing Product Introduction
• 1.2 Global DNA Sequencing Market Size Forecast (2020-2031)
• 1.3 DNA Sequencing Market Trends & Drivers
  • 1.3.1 DNA Sequencing Industry Trends
  • 1.3.2 DNA Sequencing Market Drivers & Opportunity
  • 1.3.3 DNA Sequencing Market Challenges
  • 1.3.4 DNA Sequencing Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global DNA Sequencing Players Revenue Ranking (2024)
• 2.2 Global DNA Sequencing Revenue by Company (2020-2025)
• 2.3 Key Companies DNA Sequencing Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies DNA Sequencing Product Offered
• 2.5 Key Companies Time to Begin Mass Production of DNA Sequencing
• 2.6 DNA Sequencing Market Competitive Analysis
  • 2.6.1 DNA Sequencing Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by DNA Sequencing Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DNA Sequencing as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 First Generation DNA Sequencing
  • 3.1.2 Second Generation DNA Sequencing
  • 3.1.3 Third Generation DNA Sequencing
• 3.2 Global DNA Sequencing Sales Value by Type
  • 3.2.1 Global DNA Sequencing Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global DNA Sequencing Sales Value, by Type (2020-2031)
  • 3.2.3 Global DNA Sequencing Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Academic Research
  • 4.1.2 Clinical Research
  • 4.1.3 Hospitals and Clinics
  • 4.1.4 Pharmaceuticals and Biotechnology
  • 4.1.5 Other
• 4.2 Global DNA Sequencing Sales Value by Application
  • 4.2.1 Global DNA Sequencing Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global DNA Sequencing Sales Value, by Application (2020-2031)
  • 4.2.3 Global DNA Sequencing Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global DNA Sequencing Sales Value by Region
  • 5.1.1 Global DNA Sequencing Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global DNA Sequencing Sales Value by Region (2020-2025)
  • 5.1.3 Global DNA Sequencing Sales Value by Region (2026-2031)
  • 5.1.4 Global DNA Sequencing Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America DNA Sequencing Sales Value, 2020-2031
  • 5.2.2 North America DNA Sequencing Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe DNA Sequencing Sales Value, 2020-2031
  • 5.3.2 Europe DNA Sequencing Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific DNA Sequencing Sales Value, 2020-2031
  • 5.4.2 Asia Pacific DNA Sequencing Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America DNA Sequencing Sales Value, 2020-2031
  • 5.5.2 South America DNA Sequencing Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa DNA Sequencing Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa DNA Sequencing Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions DNA Sequencing Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions DNA Sequencing Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States DNA Sequencing Sales Value, 2020-2031
  • 6.3.2 United States DNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States DNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe DNA Sequencing Sales Value, 2020-2031
  • 6.4.2 Europe DNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe DNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China DNA Sequencing Sales Value, 2020-2031
  • 6.5.2 China DNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China DNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan DNA Sequencing Sales Value, 2020-2031
  • 6.6.2 Japan DNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan DNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea DNA Sequencing Sales Value, 2020-2031
  • 6.7.2 South Korea DNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea DNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia DNA Sequencing Sales Value, 2020-2031
  • 6.8.2 Southeast Asia DNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia DNA Sequencing Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India DNA Sequencing Sales Value, 2020-2031
  • 6.9.2 India DNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India DNA Sequencing Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Illumina
  • 7.1.1 Illumina Profile
  • 7.1.2 Illumina Main Business
  • 7.1.3 Illumina DNA Sequencing Products, Services and Solutions
  • 7.1.4 Illumina DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Illumina Recent Developments
• 7.2 Thermo Fisher Scientific
  • 7.2.1 Thermo Fisher Scientific Profile
  • 7.2.2 Thermo Fisher Scientific Main Business
  • 7.2.3 Thermo Fisher Scientific DNA Sequencing Products, Services and Solutions
  • 7.2.4 Thermo Fisher Scientific DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Thermo Fisher Scientific Recent Developments
• 7.3 Eurofins Scientific
  • 7.3.1 Eurofins Scientific Profile
  • 7.3.2 Eurofins Scientific Main Business
  • 7.3.3 Eurofins Scientific DNA Sequencing Products, Services and Solutions
  • 7.3.4 Eurofins Scientific DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Eurofins Scientific Recent Developments
• 7.4 BGI
  • 7.4.1 BGI Profile
  • 7.4.2 BGI Main Business
  • 7.4.3 BGI DNA Sequencing Products, Services and Solutions
  • 7.4.4 BGI DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.4.5 BGI Recent Developments
• 7.5 Natera
  • 7.5.1 Natera Profile
  • 7.5.2 Natera Main Business
  • 7.5.3 Natera DNA Sequencing Products, Services and Solutions
  • 7.5.4 Natera DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Natera Recent Developments
• 7.6 Berry Genomics
  • 7.6.1 Berry Genomics Profile
  • 7.6.2 Berry Genomics Main Business
  • 7.6.3 Berry Genomics DNA Sequencing Products, Services and Solutions
  • 7.6.4 Berry Genomics DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Berry Genomics Recent Developments
• 7.7 Roche
  • 7.7.1 Roche Profile
  • 7.7.2 Roche Main Business
  • 7.7.3 Roche DNA Sequencing Products, Services and Solutions
  • 7.7.4 Roche DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Roche Recent Developments
• 7.8 Novo Gene
  • 7.8.1 Novo Gene Profile
  • 7.8.2 Novo Gene Main Business
  • 7.8.3 Novo Gene DNA Sequencing Products, Services and Solutions
  • 7.8.4 Novo Gene DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Novo Gene Recent Developments
• 7.9 MGI-Tech
  • 7.9.1 MGI-Tech Profile
  • 7.9.2 MGI-Tech Main Business
  • 7.9.3 MGI-Tech DNA Sequencing Products, Services and Solutions
  • 7.9.4 MGI-Tech DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.9.5 MGI-Tech Recent Developments
• 7.10 LabCorp
  • 7.10.1 LabCorp Profile
  • 7.10.2 LabCorp Main Business
  • 7.10.3 LabCorp DNA Sequencing Products, Services and Solutions
  • 7.10.4 LabCorp DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.10.5 LabCorp Recent Developments
• 7.11 Pacific Biosciences
  • 7.11.1 Pacific Biosciences Profile
  • 7.11.2 Pacific Biosciences Main Business
  • 7.11.3 Pacific Biosciences DNA Sequencing Products, Services and Solutions
  • 7.11.4 Pacific Biosciences DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.11.5 Pacific Biosciences Recent Developments
• 7.12 Azenta Life Sciences
  • 7.12.1 Azenta Life Sciences Profile
  • 7.12.2 Azenta Life Sciences Main Business
  • 7.12.3 Azenta Life Sciences DNA Sequencing Products, Services and Solutions
  • 7.12.4 Azenta Life Sciences DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Azenta Life Sciences Recent Developments
• 7.13 Oxford Nanopore
  • 7.13.1 Oxford Nanopore Profile
  • 7.13.2 Oxford Nanopore Main Business
  • 7.13.3 Oxford Nanopore DNA Sequencing Products, Services and Solutions
  • 7.13.4 Oxford Nanopore DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Oxford Nanopore Recent Developments
• 7.14 Macrogen
  • 7.14.1 Macrogen Profile
  • 7.14.2 Macrogen Main Business
  • 7.14.3 Macrogen DNA Sequencing Products, Services and Solutions
  • 7.14.4 Macrogen DNA Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.14.5 Macrogen Recent Developments

8 Industry Chain Analysis

• 8.1 DNA Sequencing Industrial Chain
• 8.2 DNA Sequencing Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 DNA Sequencing Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 DNA Sequencing Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer